Feature | March 12, 2014

Partnership Investigates Remote Robotic PCI at Rural Hospitals

Corindus CorPath Robotic Navigation Telemedicine Telecardiology Cath Lab

March 12, 2014 — For patients living in rural areas, life-saving procedures such as an angioplasty may only be available at a facility more than 200 miles away. To bridge this distance, Corindus Vascular Robotics is partnering with Sanford Health and The Leona M. and Harry B. Helmsley Charitable Trust to launch a feasibility study for a remote robotic systems cath lab telecardiology program. 

Following the feasibility study, the remote robotics program is intended to potentially empower an interventional cardiologist at a major center to robotically control the movement of interventional devices at a remote facility. This could offer patients located in rural areas the high-quality heart care and treatment currently available only at heart centers in major metropolitan areas. The first phase of the program aims to understand what is required to make remote robotics successful. The development of the program will proceed based on those findings.

With funding from The Leona M. and Harry B. Helmsley Charitable Trust, Corindus and Sanford Health will pursue pioneering remote capabilities for robotic-assisted percutaneous coronary intervention (PCI).

CorPath is an U. S. Food and Drug Administration (FDA)-cleared technology. It enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Physicians sit in a lead-lined interventional cockpit protected from radiation exposure. CorPath allows the cardiologist to advance stents and guidewires millimeter-by-millimeter using joysticks and touchscreen controls. The remote robotics program is intended to extend the capability of CorPath to not just perform angioplasty in the same cath lab, but in labs hundreds of miles away. 

For more information: www.corindus.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now